ComprehensiveOffering Provides Flexible Access to Key Quality Processes
Sparta Systems, Inc., an industry pioneer and global leader in enterprise quality management software (EQMS) solutions, today announced the availability of a comprehensive mobile solution product suite designed to improve the operational efficiency and effectiveness of its customers’ increasingly mobile workforce. Organizations are now able to significantly expand the reach of their quality processes, reporting and analytics beyond the four walls of their businesses.
Sparta Systems’ mobile product suite includes:
These Sparta Systems’ mobile offerings provide the following business and usability benefits:
“The launch of Sparta System’s mobile product suite underscores our continued commitment and investment in our customers,” said Eileen Martinson, Chief Executive Officer. “The entirely reinvented mobile user experience, combined with delivery as a turnkey service will rapidly accelerate customers’ time to adoption and realization of value.”
TrackWise Mobile product suite has been optimized to work on most Apple iOS devices, with support for Android devices expected later this quarter. To learn more view the TrackWise Mobile video or visit www.spartasystems.com.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.